The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Neoadjuvant treatment with disitamab vedotin plus perioperative toripalimab in patients with muscle-invasive bladder cancer (MIBC) with HER2 expression: Updated efficacy and safety results from the phase II RC48-C017 trial.
 
Xinan Sheng
Speakers' Bureau - Astellas Pharma; Junshi Pharmaceuticals; MSD Oncology; Pfizer; RemeGen
 
Cuijian Zhang
No Relationships to Disclose
 
Yongpeng Ji
No Relationships to Disclose
 
Li Zhou
No Relationships to Disclose
 
Benkui Zou
No Relationships to Disclose
 
Hang Huang
No Relationships to Disclose
 
Yonghua Wang
No Relationships to Disclose
 
Kaiwei Yang
No Relationships to Disclose
 
Xue Bai
Employment - RemeGen
 
Dan Feng
Employment - RemeGen
 
Yong Yang
No Relationships to Disclose
 
Jiasheng Bian
No Relationships to Disclose
 
Zhixian Yu
No Relationships to Disclose
 
Haitao Niu
No Relationships to Disclose
 
Peng Du
No Relationships to Disclose
 
Jianmin Fang
Employment - RemeGen
 
Zhisong He
No Relationships to Disclose
 
Jun Guo
Consulting or Advisory Role - Bayer; MSD; Novartis; Oriengene; Pfizer; Roche; Shanghai Junshi BioSciences; Simcere